AIP
PFE icon

Almanack Investment Partners’s Pfizer PFE Stock Holding History

Almanack Investment Partners’s Portfolio PFE Stock Details PFE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$607K Buy
25,225
+15,580
+162% +$408K 0.08% 146
2026
Q1 		$271K Hold
9,645
– – 0.05% 143
2025
Q4 		$240K Buy
9,645
+90
+0.9% +$2.27K 0.04% 147
2025
Q3 		$243K Buy
+9,555
New +$236K 0.04% 172
2023
Q4 		– Sell
-8,029
Closed -$266K – 179
2023
Q3 		$266K Sell
8,029
-7,568
-49% -$268K 0.05% 127
2023
Q2 		$572K Sell
15,597
-2,129
-12% -$82.9K 0.1% 84
2023
Q1 		$723K Sell
17,726
-633
-3% -$27.3K 0.14% 72
2022
Q4 		$941K Buy
+18,359
New +$880K 0.2% 55
2022
Q3 		– Sell
-30,806
Closed -$1.61M – 870
2022
Q2 		$1.61M Buy
30,806
+5,588
+22% +$285K 0.16% 94
2022
Q1 		$1.31M Buy
25,218
+282
+1% +$14.6K 0.11% 121
2021
Q4 		$1.47M Buy
24,936
+1,885
+8% +$93.4K 0.12% 116
2021
Q3 		$991K Buy
23,051
+1,896
+9% +$84K 0.09% 162
2021
Q2 		$828K Sell
21,155
-1,846
-8% -$71.8K 0.08% 159
2021
Q1 		$833K Sell
23,001
-528
-2% -$18.7K 0.08% 156
2020
Q4 		$866K Buy
23,529
+7,212
+44% +$265K 0.1% 130
2020
Q3 		$605K Buy
16,317
+3,754
+30% +$132K 0.07% 173
2020
Q2 		$390K Sell
12,563
-1,811
-13% -$61.5K 0.07% 150
2020
Q1 		$445K Buy
14,374
+6,442
+81% +$220K 0.1% 134
2019
Q4 		$295K Sell
7,932
-70
-0.9% -$2.49K 0.06% 146
2019
Q3 		$273K Sell
8,002
-89
-1% -$3.24K 0.05% 171
2019
Q2 		$333K Buy
+8,091
New +$321K 0.08% 129
2019
Q1 		– Sell
-4,768
Closed -$197K – 186
2018
Q4 		$197K Buy
4,768
+63
+1% +$2.62K 0.06% 153
2018
Q3 		$198K Buy
+4,705
New +$181K 0.05% 178
2017
Q2 		– Sell
-7,693
Closed -$250K – 197
2017
Q1 		$250K Buy
+7,693
New +$243K 0.19% 84

Other funds holding PFE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Almanack Investment Partners's PFE Position: Q2 2026 in Review

Almanack Investment Partners increased its Pfizer (PFE) stake by 162% in Q2 2026, buying an estimated $408K and bringing the position to 25,225 shares worth $607K. The position accounts for 0.08% of the portfolio, ranked #146.

Almanack Investment Partners first reported a position in PFE in Q1 2017 and has held it in 24 quarters since. The position peaked at $1.61M in Q2 2022. 2,822 funds tracked by Wall St. Rank hold PFE as of Q2 2026.

  • Almanack Investment Partners held 25,225 shares of Pfizer worth $607K as of Q2 2026.
  • Almanack Investment Partners bought 15,580 Pfizer shares in Q2 2026, an estimated $408K.
  • Pfizer made up 0.08% of Almanack Investment Partners's portfolio in Q2 2026, its #146 holding.
  • Almanack Investment Partners first reported a position in Pfizer in Q1 2017 and has held it in 24 quarters since.
  • Almanack Investment Partners's Pfizer position peaked at $1.61M in Q2 2022.
  • 2,822 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.

Based on Almanack Investment Partners's 13F filing for Q2 2026, filed 30 Jul 2026.